Pyrrolidine CB2 Agonists for Selective Anti-Inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic applications of cannabinoids are limited by their psychoactive effects, addiction potential, and lack of specificity in targeting inflammatory and pain conditions, as they primarily act on CB1 receptors, which also mediate euphoric effects.
Innovation Solution
Development of novel compounds that selectively modulate the CB2 receptor, acting as agonists to treat inflammation and pain without the psychoactive effects associated with CB1 receptor activation, by binding to specific structures and configurations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoids are used to treat inflammation and pain, then therapeutic effects are achieved, but psychoactive side effects occur due to CB1 receptor activation
Solution Approach 1:
The patent develops compounds with selective affinity for CB2 receptors over CB1 receptors, creating local specificity in receptor targeting. The chemical structures are designed to preferentially bind to CB2 receptors in peripheral tissues and immune cells while minimizing interaction with CB1 receptors in the central nervous system, thereby achieving anti-inflammatory and analgesic effects without psychoactive side effects
Solution Approach 2:
The patent segments the cannabinoid receptor system into two distinct targets (CB1 and CB2) and designs compounds that selectively modulate only the CB2 segment. This segmentation allows therapeutic action through CB2 activation while avoiding the harmful effects mediated by CB1, effectively separating the beneficial and harmful pathways
2Reliability
If THC and its analogs are used for anti-emetic and appetite stimulation, then clinical benefits are achieved, but addiction and dependence occur
Solution Approach 1:
The patent creates compounds with localized action at peripheral CB2 receptors, particularly in immune cells and gastrointestinal tract, to achieve anti-emetic effects without central nervous system penetration. This local specificity prevents activation of CB1 receptors in the brain that would lead to euphoria, addiction, and dependence while maintaining therapeutic efficacy
3Adaptability or versatility
If CB1 selective agonists are used to achieve central nervous system effects, then euphoric effects are produced, but therapeutic specificity for inflammatory conditions is reduced
Solution Approach 1:
Instead of targeting CB1 receptors in the central nervous system to achieve therapeutic effects, the patent inverts the approach by selectively targeting CB2 receptors in peripheral tissues and immune cells. This inversion allows treatment of inflammatory and pain conditions through peripheral mechanisms, avoiding the need for central nervous system activation and its associated side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These CB2 receptor modulators effectively treat inflammation and pain with reduced risk of psychoactive side effects, targeting immune cells and peripheral tissues while minimizing central nervous system impact.
Implementation Method 1
These compounds bind to and modulate the CB2 receptor
Data Source
AI summary
Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. (I)